POXEL SA announced positive results from a new Phase 2 trial evaluating Imeglimin, the company's first-in-class oral anti-diabetic agent. The results demonstrate that Imeglimin met the primary and secondary endpoints with statistical significance, while confirming safety and efficacy. This Phase 2 trial was an 18-week, randomized, placebo controlled trial in 59 subjects that were treated with either 1500mg of Imeglimin twice daily or placebo.

In this trial, Imeglimin improves both fasting and post-prandial glucose control by increasing glucose-dependent insulin secretion and by improving insulin action. This unique profile translates into a significant HbA1c (glucose control) reduction of 0.62% (p=0.013) versus placebo, confirming Phase 2b and add-on therapy trial results. A significant effect on post-prandial glucose (reduction of 804 mmol.h/L, p=0.001) and on fasting plasma glucose was shown after treatment with Imeglimin (reduction of 1.22mmol/L, p=0.022).

Imeglimin was also able to significantly increase insulin secretion and insulin sensitivity indexes in response to glucose during a challenge test.